Concert Pharma Sees US Application Submission For Patchy Hair Loss Candidate In 2023

Concert Pharmaceuticals Inc CNCE has announced updated data from its ongoing open-label, long-term extension study of CTP-543 in patients with moderate to severe alopecia areata.
Alopecia areata is an autoimmune disorder that results in patchy or complete hair loss.
The data showed that relative to the previous Phase 2 study results of CTP-543, hair regrowth was maintained or improved in the majority of patients through one year of continuous dosing with 12 mg twice-daily of CTP-543.
Approximately 57% of participants receiving 12 mg of CTP-543 twice-daily following 52 weeks of dosing achieved a clinically meaningful disease severity score of 20 or less.
Dosing in the long-term extension study is ongoing, and patients completing the ongoing Phase 3 THRIVE-AA trials are eligible to enroll in the study.
These data will be presented virtually during the virtual JAK Inhibitors Drug Development Summit.
The company plans to file a marketing application in early 2023.
Price Action: CNCE shares are down 2.65% at $4.11 during the market session on the last check Thursday.